Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

Investigational New Drugs

Volumn 27, Issue 2, 2009, Pages 179-183

  Gullo, Giuseppe ^a   Bettio, Daniela ^a   Torri, Valter ^b   Masci, Giovanna ^a   Salvini, Piermario ^c   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c Humanitas Gavazzeni Hospital   (Italy)

Author keywords

FISH; Metastatic breast cancer; Monoclonal antibody; Predictive factor; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; CENTRAL NERVOUS SYSTEM; CENTROMERE; CHROMOSOME 17; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATION ANALYSIS; DISEASE COURSE; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; HER2 GENE; HUMAN; METASTASIS; OVERALL SURVIVAL; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RELIABILITY; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TIME TO PROGRESSION; BREAST TUMOR; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROTO ONCOGENE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 66949136442     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9155-y     Document Type: Article

References (20)

1. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene Science 235 177 182 (Pubitemid 17231334)
2. S Ménard P Casalini G Tomasic 1999 Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors Breast Cancer Res Treat 55 169 177 (Pubitemid 29389579)
3. DJ Slamon B Leyland-Jones S Shak 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 (Pubitemid 32222155)
4. CL Vogel MA Cobleigh D Tripathy 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726 (Pubitemid 34111379)
5. M Marty F Cognetti D Maraninchi 2005 Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group J Clin Oncol 23 4265 4274 (Pubitemid 46207001)
6. AC Wolff ME Hammond JN Schwartz 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 (Pubitemid 350003059)
7. MD Pegram G Pauletti DJ Slamon 1998 HER-2/neu as a predictive marker of response to breast cancer therapy Breast Cancer Res Treat 52 65 77 (Pubitemid 29056086)
8. C Lohrisch M Piccart 2001 HER2/neu as a predictive factor in breast cancer Clin Breast Cancer 2 129 135 (Pubitemid 32771564)
9. RD Mass MF Press S Anderson 2005 Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab Clin Breast Cancer 6 240 246 (Pubitemid 47050800)
10. AB Miller B Hoogstraten M Staquet 1981 Reporting results of cancer treatment Cancer 47 207 214 (Pubitemid 11167383)
11. M Bilous M Dowsett W Hanna 2003 Current perspectives on HER2 testing: a review of national testing guidelines Mod Pathol 16 173 182 (Pubitemid 36245750)
12. R Giuliani V Durbecq A Di Leo 2007 Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC) Eur J Cancer 43 725 735 (Pubitemid 46509445)
13. T Fujita H Doihara K Kawasaki 2006 PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer Br J Cancer 94 247 252 (Pubitemid 43151543)
14. LN Harris F You SJ Schnitt 2007 Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer Clin Cancer Res 13 1198 1207 (Pubitemid 46424061)
15. K Berns HM Horlings BT Hennessy 2007 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395 402 (Pubitemid 47539306)
16. G Valabrega F Montemurro M Aglietta 2007 Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Ann Oncol 18 977 984 (Pubitemid 47050487)
17. M Scaltriti F Rojo A Ocaña 2007 Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer J Natl Cancer Inst 99 628 38
18. A Musolino N Naldi B Bortesi 2008 Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer J Clin Oncol 26 1789 1796
19. G Gullo D Bettio G Masci 2006 The level of HER2/neu amplification may have a correlation with some relevant histopathological features of early stage breast cancer Ann Oncol 17 s11
20. A Kallioniemi 2008 CGH microarrays and cancer Curr Opin Biotechnol 19 36 40